Myriad Genetics
MYGN
MYGN
190 hedge funds and large institutions have $1.91B invested in Myriad Genetics in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 61 increasing their positions, 75 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
19% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 75
Holders
190
Holding in Top 10
1
Calls
$17.1M
Puts
$70K
Top Buyers
| 1 | +$36.9M | |
| 2 | +$25.5M | |
| 3 | +$18.2M | |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$13.3M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.19M |
Top Sellers
| 1 | -$9.7M | |
| 2 | -$8.93M | |
| 3 | -$6.31M | |
| 4 |
EARNEST Partners
Atlanta,
Georgia
|
-$5.66M |
| 5 |
BlackRock
New York
|
-$5.31M |